Diese Übersicht kann historisch angepasste Werte enthalten, um eine Vergleichbarkeit mit dem Berichtsjahr herzustellen.
| XLS |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
in Mio € |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
Verän- | ||||||||
| |||||||||||||||||||
|
Gesamterlöse nach Sparten |
7.521 |
7.364 |
6.017 |
5.887 |
6.310 |
7.081 |
7.590 |
7.747 |
9.291 |
10.276 |
11 | ||||||||
|
Pharma |
3.265 |
3.458 |
3.601 |
3.905 |
4.163 |
4.900 |
5.456 |
5.812 |
6.226 |
6.416 |
3,1 | ||||||||
|
Merck Serono |
1.850 |
1.546 |
1.619 |
1.817 |
1.938 |
4.480 |
5.014 |
5.345 |
5.754 |
5.920 |
2,9 | ||||||||
|
Generics1 |
1.096 |
1.585 |
1.625 |
1.712 |
1.825 |
– |
– |
– |
– |
– |
– | ||||||||
|
Consumer Health Care |
319 |
327 |
357 |
376 |
400 |
420 |
442 |
467 |
472 |
496 |
5,1 | ||||||||
|
Chemie |
1.791 |
1.707 |
1.696 |
1.906 |
2.113 |
2.152 |
2.127 |
1.935 |
3.065 |
3.860 |
26 | ||||||||
|
Merck Millipore |
– |
– |
– |
– |
– |
– |
– |
– |
1.6134 |
2.393 |
48 | ||||||||
|
Performance Materials |
– |
– |
– |
– |
– |
– |
– |
– |
1.4524 |
1.467 |
1,0 | ||||||||
|
Liquid Crystals2 |
383 |
443 |
589 |
741 |
895 |
916 |
878 |
733 |
– |
– |
– | ||||||||
|
Performance & Life Science Chemicals2 |
1.216 |
1.083 |
1.107 |
1.165 |
1.218 |
1.236 |
1.249 |
1.202 |
– |
– |
– | ||||||||
|
Electronic Chemicals1 |
192 |
181 |
– |
– |
– |
– |
– |
– |
– |
– |
– | ||||||||
|
Labordistribution1 |
2.711 |
2.427 |
582 |
– |
– |
– |
– |
– |
– |
– |
– | ||||||||
|
Innenumsätze Labor |
–246 |
–228 |
–62 |
– |
– |
– |
– |
– |
– |
– |
– | ||||||||
|
Konzernkosten und Sonstiges |
– |
– |
200 |
76 |
34 |
29 |
7 |
– |
– |
– |
– | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
Operatives Ergebnis nach Unternehmensbereichen |
616 |
736 |
776 |
883 |
1.105 |
976 |
1.131 |
649 |
1.113 |
985 |
–12 | ||||||||
|
Pharma |
272 |
389 |
391 |
454 |
524 |
417 |
655 |
403 |
579 |
350 |
–40 | ||||||||
|
Chemie |
260 |
316 |
420 |
492 |
641 |
631 |
558 |
324 |
624 |
751 |
20 | ||||||||
|
Labordistribution1 |
84 |
79 |
21 |
– |
– |
– |
– |
– |
– |
– |
– | ||||||||
|
Konzernkosten und Sonstiges |
– |
–48 |
–56 |
–63 |
–60 |
–72 |
–81 |
–78 |
–90 |
–116 |
30 | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
Ergebnis vor Zinsen und Steuern (EBIT) |
559 |
538 |
1.044 |
956 |
1.325 |
200 |
731 |
621 |
1.113 |
1.137 |
2,2 | ||||||||
|
EBIT vor Abschreibungen und Wertberichtigungen (EBITDA) |
985 |
1.008 |
1.419 |
1.245 |
1.628 |
1.858 |
1.947 |
1.625 |
2.457 |
2.736 |
11 | ||||||||
|
Ergebnis vor Steuern |
412 |
423 |
961 |
893 |
1.273 |
–111 |
575 |
486 |
861 |
851 |
–1,2 | ||||||||
|
Ergebnis nach Steuern |
215 |
218 |
672 |
673 |
1.001 |
3.5203 |
379 |
377 |
642 |
629 |
–2,0 | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
Free Cash Flow |
441 |
442 |
1.889 |
657 |
–1.073 |
–1.4733 |
438 |
812 |
–3.522 |
1.436 |
– | ||||||||
|
Investitionen in Sachanlagen |
377 |
281 |
234 |
268 |
253 |
2833 |
395 |
467 |
396 |
372 |
–6,1 | ||||||||
|
Forschung und Entwicklung |
608 |
605 |
599 |
713 |
752 |
1.028 |
1.234 |
1.345 |
1.397 |
1.517 |
8,6 | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
Bilanzsumme |
7.511 |
6.982 |
5.754 |
7.281 |
8.102 |
14.922 |
15.645 |
16.713 |
22.388 |
22.120 |
–1,2 | ||||||||
|
Eigenkapital |
2.054 |
2.363 |
2.800 |
3.329 |
3.807 |
8.688 |
9.563 |
9.514 |
10.372 |
10.493 |
1,2 | ||||||||
|
Mitarbeiter (Anzahl 31.12.) |
34.504 |
34.206 |
28.877 |
29.133 |
29.999 |
30.968 |
32.800 |
33.062 |
40.562 |
40.676 |
0,3 | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
Umsatzrendite in % (ROS: Operatives Ergebnis / Gesamterlöse) |
8,2 |
10,0 |
12,9 |
15,0 |
17,5 |
13,8 |
14,9 |
8,4 |
12,0 |
9,6 |
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
Ergebnis je Aktie in € |
1,18 |
1,15 |
3,47 |
3,40 |
5,07 |
16,213 |
1,69 |
1,68 |
2,91 |
2,84 |
–2,4 | ||||||||
|
Dividende je Aktie in € |
1,00 |
0,80 |
0,80 |
0,85 |
0,90 |
1,20 |
1,50 |
1,00 |
1,25 |
1,50 |
20 | ||||||||
|
Einmaliger Bonus je Aktie in € |
– |
– |
0,20 |
– |
0,15 |
2,00 |
– |
– |
– |
– |
– | ||||||||
